After receiving an initial single dose of the HPV vaccine Gardasil 9, children aged 9 to 11 had high levels of two key antibodies that protect against HPV infections and cancer for up to 2 years before receiving their delayed booster dose, according to results from a clinical trial supported by NCI. The trial is the first conducted in the United States to demonstrate that a single dose of Gardasil 9 generates a sustained immune response up to 2 years against the two most prominent cancer-causing types of HPV—HPV16 and HPV18.

Read the blog.

View the latest issue of ULACNet Update, your source for programmatic and research updates for the US-Latin American-Caribbean HIV/HPV-Cancer Prevention Clinical Trials Network (ULACNet). This issue covers an IPVC round up, a guest contributor on women living with HIV and fighting HPV, ULACNet-301 opening in Brazil, ULACNet-202 site initiation visits in Brazil & Mexico, and training health care professionals caring for persons living HIV/HPV.

To receive future issues, subscribe to ULACNet Update.

NOT-AG-22-048

This NOSI encourages applications focused on palliative care in geriatric populations in a variety of settings including hospitals (and specific sites within hospitals including specialty medical or surgical wards, intensive care units, and emergency departments), post-acute care settings, outpatient clinics and doctors’ offices, patients’ homes and other residential settings, long-term care facilities, hospices, and other health care or community settings.  

Expires: 9/8/23 

NOT-CA-22-001

NCI encourages applications that support collaborative and innovative approaches to reduce cardiovascular dysfunction while improving cancer outcomes by understanding the mechanisms of cancer treatment-related cardiotoxicity and translating the findings to improve risk stratification, early detection, prevention, and management. 

Expires: 11/6/24

Patient-Clinician Relationship: Improving Health Outcomes in Populations that Experience Health Care Disparities 

PAR-22-064

NCI invites applications to support innovative multi-disciplinary and multi-level (e.g., patient, clinician, interpersonal, health care system, community) research designed to understand how optimizing patient-clinician communication and relationships affects health care outcomes in patients from populations that experience health care disparities.

Expires: 1/8/25

NOSI: Administrative Supplements for Enhancing Recruitment and Retention of Diverse Populations to Cancer Screening, Cancer Prevention, and Symptom Management Clinical Trials 

NOT-CA-23-071

Current NCI grant or cooperative agreement awardees are encouraged to apply for administrative supplement funds to support the development of tools and strategies to increase the participation of individuals who are representative of people for whom the parent grant intervention may be indicated. The proposed strategies and tools should be designed to promote inclusion of historically underserved populations in clinical trials by identifying and reducing enrollment barriers at the organizational, participant, or protocol design level.  

Expires: 7/1/25

NCI Clinical and Translational Exploratory/Developmental Studies 

PAR-22-216

NCI invites applications to support research and correlative studies directly related to advancements in cancer treatment, diagnosis, prevention, comparative oncology, symptom management, or reduction of cancer disparities. This includes development and testing of new molecular agents or biologics for cancer treatment; management strategies for cancer-related symptoms or treatment-related toxicity; cancer screening or diagnostic tools, such as imaging techniques; cancer preventive agents or approaches; predictive and prognostic biomarkers for patient selection or stratification; clinically relevant in vivo or in vitro tumor models; and strategies to address therapeutic outcome disparities among underserved populations.  

Expires: 7/2/25